Updated with additional information.
Nine months of treatment with an experimental pill from Madrigal Pharmaceuticals resulted in the significant reversal of the fatty liver disease known as NASH, according to updated data from a placebo-controlled clinical trial released Thursday.
Isn’t that a rather large increase in share value for results in a phase 2? There’s still a long road to the market. This seems consistent with other Stat reports on excessive enthusiasm of the biotech investment community.
Comments are closed.